Entrectinib, with similar potency, inhibits anaplastic lymphoma kinase (ALK), ROS1 and tropomyosin receptor kinase (TRK), showing antiproliferative activity in cancers originating from gene fusion mutations involving these proteins. Here, ALK is linked to cancer.